The following appendix lists publications from 2024 from the Velindre Cancer Service. This listing has been compiled by Velindre University NHS Trust’s Library Service.
During 2024 there has been a total of 127 publications – 76 articles and 51 conference abstracts
B1. Breast
Articles
J. E. Abraham, K. Pinilla, A. Dayimu, L. Grybowicz, N. Demiris, C. Harvey, L. M. Drewett, R. Lucey, A. Fulton, A. N. Roberts, J. R. Worley, A. Chhabra, W. Qian, A.-L. Vallier, R. M. Hardy, S. Chan, T. Hickish, D. Tripathi, R. Venkitaraman, M. Persic, S. Aslam, D. Glassman, S. Raj, A. Borley, J. P. Braybrooke, S. Sutherland, E. Staples, L. C. Scott, M. Davies, C. A. Palmer, M. Moody, M. J. Churn, J. C. Newby, M. B. Mukesh, A. Chakrabarti, R. R. Roylance, P. C. Schouten, N. C. Levitt, K. McAdam, A. C. Armstrong, E. R. Copson, E. McMurtry, M. Tischkowitz, E. Provenzano and H. M. Earl (2024). "The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer." Nature 629(8014): 1142-1148.
J. D. Benitez Fuentes, E. Morgan, A. de Luna Aguilar, A. Mafra, R. Shah, F. Giusti, J. Vignat, A. Znaor, C. Musetti, C.-H. Yip, L. Van Eycken, E. Jedy-Agba, M. Pineros and I. Soerjomataram (2024). "Global Stage Distribution of Breast Cancer at Diagnosis: A Systematic Review and Meta-Analysis." JAMA oncology 10(1): 71-78.
J. D. Benitez Fuentes, E. Morgan and I. Soerjomataram (2024). "Clarification Regarding Breast Cancer Stage in France-Reply." JAMA oncology 10(6): 832-833.
M. K. Bishr, J. Banks, M. S. Abdelaziz, M. Badawi, P. W. Crane, U. J. Donigiewicz, M. Elkorety, M. Girgis, A. Humphreys, J. Isherwood, J. Kahan, S. Keelan, E. K. Lindqvist, I. Nixon, H. Sackey, C. Sars, H. Soliman, N. Touqan, D. D. Remoundos and M. Ahmed (2024). "Multidisciplinary Management of Phyllodes Tumours and Breast Sarcoma: A Cross-sectional Survey of Clinical Practice across the UK and Ireland." Clinical oncology (Royal College of Radiologists (Great Britain)) 36(1): e31-e39.
M. Coakley, G. Villacampa, P. Sritharan, C. Swift, K. Dunne, L. Kilburn, K. Goddard, C. Pipinikas, P. Rojas, W. Emmett, P. Hall, C. Harper-Wynne, T. Hickish, I. Macpherson, A. Okines, A. Wardley, D. Wheatley, S. Waters, C. Palmieri, M. Winter, R. J. Cutts, I. Garcia-Murillas, J. Bliss and N. C. Turner (2024). "Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research 30(4): 895-903.
A. Glaviano, S. A. Wander, R. D. Baird, K. C. H. Yap, H. Y. Lam, M. Toi, D. Carbone, B. Geoerger, V. Serra, R. H. Jones, J. Ngeow, E. Toska, J. Stebbing, K. Crasta, R. S. Finn, P. Diana, K. Vuina, R. A. M. de Bruin, U. Surana, A. Bardia and A. P. Kumar (2024). "Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment." Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 76: 101103.
D. Hanna, S. Merrick, A. Ghose, M. J. Devlin, D. D. Yang, E. Phillips, A. Okines, N. Chopra, E. Papadimatraki, K. Ross, I. Macpherson, Z. Y. Boh, C. O. Michie, A. Swampillai, S. Gupta, T. Robinson, L. Germain, C. Twelves, C. Atkinson, A. Konstantis, P. Riddle, N. Cresti, J. D. Naik, A. Borley, A. Guppy, P. Schmid and M. Phillips (2024). "Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom." British Journal of Cancer 130(12): 1916-1920.
D. Mahmoud, M. Yassa, L. Alvarado, C. Lambert, S. Meterissian, D. Anderson, F. Tremblay, N. Otaky, J. Keyserlingk, V. Panet-Raymond, N. Kopek, M. David, M. Duclos, C. Pembroke, D. Fleiszer, A. N. Meguerditchian, A. Loutfi, D. Lavigne and T. Hijal (2024). "Single pre-operative radiation therapy (SPORT-CK) trial for low-risk breast cancer: Early results of a phase 2 study." Radiotherapy & Oncology 200: 110510.
B2. Colorectal
Articles
R. Adams, K. Drinkwater, D. C. Gilbert, M. A. Hawkins, D. Sebag-Montefiore, N. Thorpe and R. Muirhead (2024). "The Impact of National Radiotherapy Guidelines: The UK Anal Cancer Story." Clinical Oncology (Royal College of Radiologists) 36(10): 593-595.
A. Case, F. Williams, S. Prosser, H. Hutchings, T. Crosby, R. Adams, G. Jenkins and S. Gwynne (2024). "Reconsidering the Role of Radiotherapy for Inoperable Gastric Cancer: A Systematic Review of Gastric Radiotherapy Given With Definitive and Palliative Intent." Clinical Oncology (Royal College of Radiologists) 37: 103693.
R. Cohen, M. Raeisi, B. Chibaudel, Q. Shi, T. Yoshino, J. R. Zalcberg, R. Adams, C. Cremolini, E. Van Cutsem, V. Heinemann, J. Tabernero, C. J. A. Punt, D. Arnold, H. I. Hurwitz, J.-Y. Douillard, A. P. Venook, L. B. Saltz, T. S. Maughan, F. Kabbinavar, C. Bokemeyer, A. Grothey, R. J. Mayer, R. Kaplan, N. C. Tebbutt, J. Randolph Hecht, B. J. Giantonio, E. Diaz-Rubio, A. F. Sobrero, M. Peeters, M. Koopman, R. M. Goldberg, T. Andre and A. de Gramont (2024). "Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis." European journal of cancer (Oxford, England : 1990) 207: 114160.
R. Cohen, M. Raeisi, B. Chibaudel, T. Yoshino, Q. Shi, J. R. Zalcberg, R. Adams, C. Cremolini, A. Grothey, R. J. Mayer, E. Van Cutsem, J. Tabernero, H. Bando, T. Misumi, M. J. Overman, T. Andre and A. de Gramont (2024). "Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation." European journal of cancer (Oxford, England : 1990) 199: 113537.
A. Della Corte, M. Mori, F. Calabrese, D. Palumbo, F. Ratti, G. Palazzo, A. Pellegrini, D. Santangelo, M. Ronzoni, E. Spezi, A. Del Vecchio, C. Fiorino, L. Aldrighetti and F. De Cobelli (2024). "Preoperative MRI radiomic analysis for predicting local tumor progression in colorectal liver metastases before microwave ablation." International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 41(1): 2349059.
H. L. Gould, K. Amin, T. Karategos, S. Abbas, S. Olive, M. Sivananthan, A. Rela, H. Reed, C. Powell, J. Navaratnam, R. Ellis-Owen, P. Fielding, D. Mondal, S. Kihara, G. Williams, C. Morgan, J. Witczak, J. Cornish, S. Gwynne, J. Horwood, J. Torkington, R. Hargest, A. Christian, M. Davies, J. Ansell and M. S. Khan (2024). "Earlier diagnosis of small intestine neuroendocrine tumours (SI-NETs) through transformation of the South Wales NET service." Journal of Neuroendocrinology.
C. S. Karapetis, H. Liu, M. J. Sorich, L. D. Pederson, E. Van Cutsem, T. Maughan, J. Y. Douillard, C. J. O'Callaghan, D. Jonker, C. Bokemeyer, A. Sobrero, C. Cremolini, B. Chibaudel, J. Zalcberg, R. Adams, M. Buyse, M. Peeters, T. Yoshino, A. de Gramont and Q. Shi (2024). "Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database." British Journal of Cancer 130(8): 1269-1278.
H. J. Lenz, T. Liu, E. Y. Chen, Z. Horvath, I. Bondarenko, I. Danielewicz, M. Ghidini, P. Garcia-Alfonso, R. Jones, M. Aapro, Y. Zhang, J. Wang, W. Wang, J. Adeleye, A. Beelen and J. Hubbard (2024). "Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial." JNCI Cancer Spectrum 23: 23.
E. Robinson, R. Balasubramaniam, M. Hameed, C. Clarke, S. A. Taylor, D. Tolan and K. G. Foley (2024). "Survey of rectal cancer MRI technique and reporting tumour descriptors in the UK: a multi-centre British Society of Gastrointestinal and Abdominal Radiology (BSGAR) audit." Clinical Radiology 79(2): 117-123.
Conference Abstracts
T. Andre, M. Raeisi, Q. Shi, T. Yoshino, J. R. Zalcberg, R. A. Adams, C. Cremolini, A. Grothey, R. J. Mayer, J. Li, B. Chibaudel and A. De Gramont (2024). "Prognostic value of liver metastases, KRAS mutations and race in colorectal cancer patients: A pooled analysis of third-line placebo-controlled trials from the ARCAD database." Annals of Oncology 35(Supplement 2): S446-S447.
M. Raeisi, R. Cohen, B. Chibaudel, H. Hurwitz, L. Saltz, F. Kabbinavar, N. Tebbutt, T. Maughan, J. Y. Douillard, E. Van Cutsem, C. Bokemeyer, R. A. Adams, J. R. Zalcberg, T. Yoshino, C. Cremolini, Q. Shi, T. Andre and A. De Gramont (2024). "7P Molecular targeted therapies based on metastatic site in first-line treatment for colorectal cancer patients: An ARCAD pooled analysis." ESMO Open 9(Supplement 1): 102262.
B3. Gynecology
Articles
N. Colombo, E. Biagioli, K. Harano, F. Galli, E. Hudson, Y. Antill, C. H. Choi, M. Rabaglio, F. Marme, C. Marth, G. Parma, L. Farinas-Madrid, S. Nishio, K. Allan, Y. C. Lee, E. Piovano, B. Pardo, S. Nakagawa, J. McQueen, C. Zamagni, L. Manso, K. Takehara, G. Tasca, A. Ferrero, G. Tognon, A. A. Lissoni, M. Petrella, M. E. Laudani, E. Rulli, S. Uggeri and M. P. Barretina Ginesta (2024). "Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial." Lancet Oncology 25(9): 1135-1146.
A. George, R. A. Herbertson, A. Stillie, S. McCormack, A. M. Drean, A. Wesselbaum, E. Hudson, T. Miles, N. A. J. Ryan, H. Maxwell, L. Le Treust and M. McCormack (2024). "Current Management Practices for Endometrial Cancer (EC) in the UK: A National Healthcare Professional Survey (KNOW-EC)." Clinical Oncology. 36(11): e448-e455.
M. McCormack, G. Eminowicz, D. Gallardo, P. Diez, L. Farrelly, C. Kent, E. Hudson, M. Panades, T. Mathew, A. Anand, M. Persic, J. Forrest, R. Bhana, N. Reed, A. Drake, M. Adusumalli, A. Mukhopadhyay, M. King, K. Whitmarsh, J. McGrane, N. Colombo, C. Mak, R. Mandal, R. R. Chowdhury, G. Alamilla-Garcia, A. Chavez-Blanco, H. Stobart, A. Feeney, S. Vaja, A. M. Hacker, A. Hackshaw and J. A. Ledermann (2024). "Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial." Lancet 404(10462): 1525-1535.
J. Morrison, P. Baldwin, L. Hanna, A. Andreou, L. Buckley, L. Durrant, K. Edey, A. Faruqi, C. Fotopoulou, R. Ganesan, K. Hillaby and A. Taylor (2024). "British Gynaecological Cancer Society (BGCS) vulval cancer guidelines: An update on recommendations for practice 2023." European journal of obstetrics, gynecology, and reproductive biology 292: 210-238.
E. Moss, A. Taylor, A. Andreou, C. Ang, R. Arora, A. Attygalle, S. Banerjee, R. Bowen, L. Buckley, N. Burbos, S. Coleridge, R. Edmondson, M. El-Bahrawy, C. Fotopoulou, J. Frost, R. Ganesan, A. George, L. Hanna, B. Kaur, R. Manchanda, H. Maxwell, A. Michael, T. Miles, C. Newton, S. Nicum, N. Ratnavelu, N. Ryan, S. Sundar, K. Vroobel, A. Walther, J. Wong and J. Morrison (2024). "British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024." European Journal of Obstetrics, Gynecology, & Reproductive Biology 300: 69-123.
N. B. Ottevanger, M. D'Incalci, R. Chekerov, G. B. Nyvang, M. Iglesias, G. Tasca, U. De Giorgi, P. Benedetti Panici, A. Westermann, I. Tsibulak, N. Colombo, A. Gadducci, E. Rulli, E. Biagioli, R. Fossati, G. Funari, L. Carlucci, D. Poli, M. C. Caudana, M. O. Nicoletto, G. Tognon, A. DeCensi, P. Zola, D. Katsaros, I. Palaia, M. Aglietta, V. Arcangeli, C. Zamagni, A. Bologna, A. Bertolini, C. Caroti, M. Bruzzone, N. Donadello, G. Di Costanzo, A. Zaniboni, D. Surico, R. Buosi, E. Cortesi, E. Zafarana, V. Fusco, L. Zavallone, T. Gamucci, F. Narducci, V. Musacchi, L. Babilonti, A. Ferrero, L. Cavanna, R. Sabbatini, S. Tamberi, M. R. Gentili, G. Artioli, A. Ardizzoia, A. Caldara, Z. Sirotova, C. Casartelli, M. Aieta, S. Cinieri, E. De Marino, S. Gori, F. Ferrau, L. Blasi, M. Alu, S. De Placido, C. Milandri, C. Churruca Galaz, M. P. Barretina-Ginesta, I. Bover, M. Romeo, B. Pardo, M. J. Rubio-Perez, A. Poveda, A. Santaballa, R. Marquez, J. Alarcon, C. Caballero-Diaz, N. Ruiz Miravet, E. Ortega, M. A. Arcusa Lanza, S. Catot Tort, R. Girones, Y. Garcia, C. Mendiola, A. B. Sanchez, E. Garcia Martinez, J. Sehouli, M. Deryal, P. Wimberger, G. Heinrich, I. Runnebaum, F. Trillsch, G. Oskay-Ozcelik, M. de Wit, E. M. Grischke, D. Bauerschlag, F. Heitz, A. Mustea, T. Fehm, A. Heider, M. Dieterich, M. Groop-Meier, M. Battista, A. Woeckel, I. Meinhold-Heerlein, A. Montes, R. Herbertson, E. Hudson, R. Bowen, I. Vergote, L. D'Hondt, P. Vuylsteke, C. Vulsteke, P. B. Ottevanger, A. M. Westermann, C. Sessa, S. Riniker, V. Heinzelmann-Schwarz, R. Von Moos, E. Kralidis, M. Mueller, S. Aebi, C. Uhlmann Nussbaum, M. Fehr, A. Muller, C. Taverna, J. Maenpaa, G. B. Nyvang, M. R. Mirza, G. B. Kristensen, A. G. Bentzen, B. Fiane, U. Puistola, M. Anttila, C. Marth, R. Berger, E. Petru, C. Schauer and A. Reinthaller (2023). "INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line." British Journal of Cancer 128(8): 1503-1513.
Conference Abstracts
M. P. B. Ginesta, S. Uggeri, K. Harano, F. Galli, E. Hudson, Y. Antill, S. W. Kim, M. Rabaglio, I. Braicu, R. Berger, H. Lin, E. Baldini, A. Redondo, K. Takehara, K. Allan, Y. C. Lee, I. Palaia, C. Casanova, F. Villa and N. Colombo (2024). "35MO Quality-adjusted survival in patients with advanced or recurrent endometrial carcinoma treated with atezolizumab in combination with carboplatin-paclitaxel versus carboplatin-paclitaxel in the AtTEnd/ENGOT-EN7 trial." ESMO Open 9(Supplement 5): 103535.
S. P. Hasson, R. Bowen, J. E. Ang, J. McGrane, I. Vazquez, A. George, J. Millar, A. Walther, E. Hudson, E. King, R. Miller, C. Green, S. Williams, R. Agarwal, D. P. Jackson, N. Patel, R. Brooks, S. Connolly, A. Tran and S. Banerjee (2024). "52P MONITOR-UK: An initial analysis of a multi-centre, observational study of maintenance niraparib in ovarian cancer." ESMO Open 9(Supplement 5): 103559.
J. Ledermann, M. McCormack, D. G. Rincon, G. Eminowicz, P. Diez, L. Farrelly, C. Kent, E. Hudson, M. Panades, T. Mathew, A. Anand, M. Persic, J. Forrest, R. Bhana, N. Reed, A. Drake, H. Stobart, A. Mukhopadhyay, A. M. Hacker and A. Hackshaw (2024). "A randomized, phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE Trial." Gynecologic Oncology Conference: The Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women's Cancer and 2024 Winter Meeting. San Diego Convention Center, San Diego United States. 2190(Supplement 2021) (pp S2021).
Y. C. Lee, N. Colombo, K. Harano, E. Rulli, E. Hudson, K. B. Lee, M. Rabaglio, I. Braicu, E. Petru, Y. C. Ou, E. Biagioli, A. Redondo, K. Takehara, K. Allan, Y. Antill, M. Lapresa, E. Piovano, G. Tasca, C. Zamagni and M. P. B. Ginesta (2024). "36MO Patient-reported outcomes in primary advanced or recurrent endometrial carcinoma treated with atezolizumab or placebo in combination with carboplatin-paclitaxel in the AtTEnd/ENGOT-EN7 trial." ESMO Open 9(Supplement 5): 103536.
B4. Head and Neck
Articles
J. D. B. Fuentes, S. Fouda, E. Evans, N. Palaniappan, T. Rackley, P. Chan, M. Evans and R. Webster (2024). "High-grade neuroendocrine head and neck cancer: Case series and review of the literature." Current problems in cancer 51: 101105.
J. T. O'Hara, C. N. Hurt, K. Ingarfield, J. M. Patterson, K. Hutcheson, J. E. Canham, L. S. Nixon, C. D. Heiberg, S. Johson, M. Evans and T. M. Jones (2024). "Transoral Laser or Robotic Surgery Outcomes for Oropharyngeal Carcinoma: Secondary Analysis of the PATHOS Randomized Clinical Trial." JAMA otolaryngology-- head & neck surgery.
S. Singer, G. Sykiotis, A. Al-Ibraheem, M. Pinto, I. Iakovou, A. A. Osthus, E. Hammerlid, L. D. Locati, E. M. Gamper, J. I. Arraras, S. Jordan, M. Buettner, D. Engesser, K. Taylor, R. Canotilho, G. Ioannidis, O. Husson, R. R. Gama, G. Fanetti, L. Moss, J. Inhestern, G. Andry, H. Rimmele and N. Kiyota (2024). "The impact of electronic versus paper-based data capture on data collection logistics and on missing scores in thyroid cancer patients." Endocrine 84(2): 635-645.
D. J. Thomson, N. J. Slevin, H. Baines, G. Betts, S. Bolton, M. Evans, K. Garcez, J. Irlam, L. Lee, N. Melillo, H. Mistry, E. More, C. Nutting, J. M. Price, S. Schipani, M. Sen, H. Yang and C. M. West (2024). "Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD)." International journal of radiation oncology, biology, physics 119(3): 771-782.
Conference Abstracts
S. Berenato, M. Evans, R. Webster, N. Palaniappan, L. Nixon, E. Higgins, R. Patel, A. E. Millin, C. Hurt, C. Heiberg, J. Canham, T. M. Jones, E. Miles, M. Beasley and P. A. Wheeler (2024). "122 Objective evaluation of plan quality in the PATHOS clinical trial using automated treatment planning." Radiotherapy and Oncology 192(Supplement 1): S29-S33.
S. Hargreaves, O. Woodley, J. Lambert, R. Maggs, T. Rackley and M. Evans (2024). "128 Impact of biological response-based adaptive radiotherapy on doses to swallowing OARS in modelled IMPT plans." Radiotherapy and Oncology 192(Supplement 1): S146-S149.
E. Higgins, R. Webster, N. Palaniappan, C. Hurt, Z. Nabi, K. Rizos, K. Elliott, E. Miles, J. Patterson, K. Hutcheson, J. Canham, L. Nixon, C. Heiberg, M. Beasley, T. M. Jones and M. Evans (2024). "49 Development of a Normal Tissue Complication Probability Model for Dysphagia in PATHOS trial patients." Radiotherapy and Oncology 192(Supplement 1): S17-S20.
K. A. Hutcheson, J. Patterson, C. Hurt, C. E. Barbon, L. J. Watson, D. Valencia, C. Alvarez, C. Heiberg, T. Jones and M. Evans (2024). "Aspiration Rates and Clinician-graded Dysphagia after Transoral Surgery (TOS): An Interim Analysis of Modified Barium Swallow (MBS) Studies (videofluoroscopy) from the PATHOS trial." International Journal of Radiation Oncology Biology Physics 118(5): e47-e48.
R. John, R. Webster, M. Evans, T. Rackley, E. Evans and N. Palaniappan (2024). "179 Contralateral Neck Recurrence Following Unilateral Treatment for Oral Tongue Squamous Cell Carcinoma." Radiotherapy and Oncology 192(Supplement 1): S210-S211.
J. T. O'Hara, C. Hurt, K. Ingarfield, J. Patterson, K. Hutcheson, C. Heiberg, M. Evans and T. Jones (2024). "121 Differential functional outcomes following transoral surgery for oropharyngeal carcinoma -laser versus robot." Radiotherapy and Oncology 192(Supplement 1): S28-S29.
J. W. Riess, J. Spicer, T. Seiwert, V. Villaflor, J. Rubio Perez, P. H. Shaw, A. Soria Rivas, M. Chaney, C. Abildgaard, P. Patel, M. Iglesias, Q. Ahmad, D. McDowell and P. Garrido Lopez (2024). "1022P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)." Annals of Oncology 35(Supplement 2): S691.
F. Williams, N. Morley, R. Webster, T. Rackley, E. Evans, M. Evans and N. Palaniappan (2024). "158 PET CT response outcomes in curatively treated oropharyngeal SCC with bulky N3 neck disease." Radiotherapy and Oncology 192(Supplement 1): S186-S187.
B5. Lung
Articles
I. Gomez-Randulfe, S. Silva Diaz, C. Escriu, S. Mohammed, R. Shah, J. D. Benitez Fuentes, S. Cox, F. Monaca, E. Bria, M. R. Garcia-Campelo, B. Crook, T. Talbot, R. Leporati, K. Balachandran, T. Newsom-Davis, S. Hughes, L. Cove-Smith, P. Taylor, F. Blackhall and R. Califano (2024). "Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis." Therapeutic advances in medical oncology 16: 17588359241272957.
A. Nelson, M. Longo, A. Byrne, S. Sivell, S. Noble, J. Lester, L. Radley, D. Jones, C. Sampson and D. Anagnostou (2024). "Chemotherapy decision-making in advanced lung cancer: a prospective qualitative study." BMJ Supportive and Palliative Care 14(e1): E758-E764.
Conference Abstracts
K. Franks, D. Smith, P. Shaw, B. Giuseppe Luigi, M. Cominos, T. Talbot, B. T. Blak, L. Lindqvist-Brown and M. Ahmed (2024). "78 Clinical outcomes in patients with unresectable stage III Non-Small Cell Lung Cancer (NSCLC) treated with durvalumab after chemoradiation in the United Kingdom: CODAK real-world study (NCT04667312)." Lung Cancer 190(Supplement 1): 107639.
E. Ghorani, M. Quartagno, F. Blackhall, M. O'Brien, C. Ottensmeier, E. Pizzo, J. Spicer, D. Gilbert, A. Baker, P. Badman, C. Milner-Watts, D. d. A. P, A. Dangoor, J. Adhikaree, J. Evans, P. Leite, M. Keni, N. Steele, F. Gomes, I. Gomez-Randulfe, P. Belitei, G. Stewart, C. Barrie, T. Geldart, P. Jain, J. K. Liu, I. Zubairi, D. Muthukumar, L. Gray, S. Treece, A. Aleksic, G. Tsaknis, E. Rathbone, P. Shaw, K. Tarver, M. K. B. Parmar and M. J. Seckl (2024). "204 REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm design." Lung Cancer 190(Supplement 1): 107765.
M. I. Gomez-Randulfe Rodriguez, C. Escriu, S. Mohammed, R. Shah, J. D. B. Fuentes, S. Cox, F. Monaca, E. Bria, S. S. Diaz, M. R. G. Campelo, B. Crook, T. Talbot, R. Leporati, K. Balachandran, T. Newsom-Davis, S. Hughes, L. Cove-Smith, P. Taylor, F. Blackhall and R. Califano (2024). "Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: An international multicentric analysis." ESMO Open 9(Supplement 3): 102774.
A. Greystoke, J. B. Oughton, S. R. Brown, K. Butterworth, V. Coyle, K. Franks, A. Hassani, S. Harrow, M. Hatton, C. T. Hiley, J. Kendall, R. Phillip, M. Norris, O. Ojo, P. Shaw, F. Walker, H. Yang, A. J. Chalmers and C. Faivre-Finn (2024). "Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology. Conference: Annual Meeting of the American Society of Clinical Oncology, ASCO 42(16 Supplement).
C. Hiley, A. Gosling, K. Durno, P. Patrick, C. Clarke, C. Gardiner, P. Shaw and N. Counsell (2024). "HIT-MESO: Hemithoracic Irradiation with Proton Therapy in Malignant Pleural Mesothelioma. UK National Proton Radiotherapy Study." Journal of Thoracic Oncology 19(10 Supplement): S411.
A. Hussnain, M. Button, N. Sahar Iqbal, C. Powell, S. Cox, C. Namelo, P. Shaw and P. Chan (2024). "80 A single-centre experience of adjuvant Durvalumab in patients with Non-small cell lung cancer (NSCLC) treated with radical concurrent chemo-radiotherapy." Lung Cancer 190(Supplement 1): 107641.
J. B. Oughton, J. Kendall, R. H. Phillip, M. Norris, A. Horne, O. Ojo, A. Greystoke, C. Faivre-Finn, F. Walker, P. H. Shaw, K. Franks, S. Harrow, C. Hiley, A. Chalmers and S. Brown (2024). "77P Experience pooling control arms within a complex phase I drug-radiotherapy (RT) platform trial." ESMO Open 9(Supplement 1): 102305.
E. Ragd Sami, P. Sabeshan, I. Datta, A. Jha, H. Abdelkhalek, S. Ahmed, T. Ahmad, S. Anum, H. Aziz, S. Baijal, R. Batool, E. Bean, L. Campbell, J. Cave, L. Cove-Smith, E. Dimitrakakis, J. Evans, A. Fares, J. Gardiner, T. Geldart, S. Gennatas, A. Georgiou, Q. Ghafoor, D. Gilligan, S. Hall, I. Harrison, H. Hassan, P. Jain, T. Janjua, E. Johnston, G. Kumar, R. Kussaibati, L. Li, D. Lobo, S. Masento, A. McGeoch, D. Muller, H. O'Beirne, C. Powell, R. Shah, N. Steele, Y. Summers, I. Tsagkaraki, T. Verissimo, G. Walls, E. Weir, E. Xing, K. Zaki, P. Zlotkowski, T. Newsom-Davis, A. Moss, P. Belitei, N. Dorey, P. Earwaker, K. Franks, I. Fraser, A. Greystoke, D. Hughes, K. Kantilal, Y. Mangan, L. Medley, D. MuthUnited Kingdomumar, C. Peedell, C. Solomon, R. Stevenson, N. Thompson, H. Turnbull, S. Walters and S. Watkins (2024). "84 National Real World Study of Adjuvant Osimertinib in Resected EGFR Mutated Lung Cancer." Lung Cancer 190(Supplement 1): 107645.
J. W. Riess, J. Spicer, T. Y. Seiwert, L. Medina, J. R. Perez, P. Shaw, L. Paz-Ares, M. F. Chaney, C. Abildgaard, A. K. Wesa, M. Iglesias, A. Pedersen, Q. Ahmad, D. O. McDowell and P. Garrido (2024). "A Phase 2 Trial of the Io102-Io103 Cancer Vaccine Plus Pembrolizumab: Results from the First-Line (1l) Cohort of Pd-L1 High Metastatic Non-Small Cell Lung Cancer (NSCLC)." Journal for ImmunoTherapy of Cancer Conference: 39th Annual Meeting of the Society for Immunotherapy of Cancer's, SITC 2024. Houston, TX United States. 2012(Supplement 2022) (pp A2860).
J. L. Vangara and M. Button (2024). "127 Perceptions of Health care professionals on Sleep disturbance amongst patients with Lung Cancer - Quality Improvement project (QIP)." Lung Cancer 190(Supplement 1): 107688.
S. Walters, A. Poon-King, A. Case, J. Maclean, J. Powell and N. S. Iqbal (2024). "149 Stereotactic radiosurgery (SRS) for the treatment of brain metastases: Outcomes for lung cancer patients in South Wales." Lung Cancer 190(Supplement 1): 107710.
A. Horne, S. Brown, K. Butterworth, A. Chalmers, F. Collinson, C. Dive, C. Faivre-Finn, M. Forster, K. Franks, A. Gilbert, M. Hallam, G. Hanna, S. Harrow, J. Hartley, C. Hiley, R. Jones, E. Katona, J. Kendall, M. Krebs, G. Mallison, J. B. Oughton, R. Phillip, D. Rothwell, D. Sebag-Montefiore, P. Shaw, G. Walls, F. Walker, R. Young and A. Greystoke (2022). "EP05.01-007 CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC)." Journal of Thoracic Oncology 17(9 Supplement): S267-S268.
B6. Melanoma
Articles
A. Dayimu, A. Gupta, R. N. Matin, J. Nobes, R. Board, M. Payne, A. Rao, A. Fusi, S. Danson, B. Eccles, J. Carser, C. O. H. Brown, N. Steven, M. Bhattacharyya, E. Brown, M. Gonzalez, M. Highley, L. Pickering, S. Kumar, A. Waterston, G. Burghel, L. Demain, E. Baker, J. Wulff, W. Qian, S. Twelves, M. Middleton and P. Corrie (2024). "A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)." European journal of cancer (Oxford, England : 1990) 196: 113455.
J. J. Sacco, R. Jackson, P. Corrie, S. Danson, T. R. J. Evans, S. Ochsenreither, S. Kumar, A. Goodman, J. Larkin, I. Karydis, N. Steven, P. Lorigan, R. Plummer, P. Patel, E. Psarelli, A. Olsson-Brown, H. Shaw, S. Leyvraz, L. Handley, C. Rawcliffe and P. Nathan (2024). "A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma." European journal of cancer (Oxford, England : 1990) 202: 114009.
Conference Abstracts
H. M. Shaw, P. M. Patel, M. Payne, S. Kumar, S. Danson, M. Highley, K. Prasad, R. Board, C. Barlow, J. Larkin, K. Young, A. Fitzpatrick, I. Karydis, M. Marples, R. Lee, P. G. Corrie, R. Miller, G. Goodhew, F. Master and L. Durrant (2024). "A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label phase 2 SCOPE trial." Journal of Clinical Oncology. Conference: Annual Meeting of the American Society of Clinical Oncology, ASCO 42(16 Supplement).
B7. Neurological
Articles
A. Duman, X. Sun, S. Thomas, J. R. Powell and E. Spezi (2024). "Reproducible and Interpretable Machine Learning-Based Radiomic Analysis for Overall Survival Prediction in Glioblastoma Multiforme." Cancers 16(19).
Conference Abstracts
J. Powell, C. Lewis, R. Burke, N. Iqbal, J. Maclean, C. John, K. Best, B. Moore, R. Davies, E. Mackay, C. Rogers, M. Kwiatkowska and S. Tindle (2024). "An Analysis of the Patient Report Outcomes of a Joint CNS / AHP Neuro-Oncology Clinic on Patients Quality of Life." Neuro-Oncology Conference: British Neuro-oncology Society Annual Meeting, BNOS 2024. Cambridge United Kingdom. 2026(Supplement 2027) (pp vii2013-vii2014).
S. Robinson, K. Ryan, L. Black, S. Forner, N. L. Hatton, R. Hatton, N. Aktar, H. Lathangue, D. Conkey, P. Durage, P. De Luna, P. Christodoulou, T. Hill, R. MacArthur, M. Teoh, A. Williams, J. Golten, T. Aghadiuno, K. Yogalingam, J. Kahan, S. Dixit, S. Guglani, R. Lewis, R. Moleron, N. Iqbal, N. Wadd, P. Bhat, G. Giamas, N. Mazarakis, C. Lorimer, E. Chandy and G. Critchley (2024). "Management of the older patient with glioblastoma in the UK: an initial report from the Histo-Mol GBM collaborative." Neuro-Oncology 26(Supplement 7): vii5 EP - vii6.
S. Robinson, K. Ryan, L. Black, S. Forner, N. L. Hatton, R. Hatton, N. Aktar, H. Lathangue, D. Conkey, P. Durage, R. MacArthur, M. Teoh, M. Choudhury, M. Bowman, C. Cavalli, P. De Luna, P. Christodoulou, T. Hill, A. Williams, J. Golten, T. Aghadiuno, K. Yogalingam, S. Lau, J. Kahan, S. Dixit, S. Guglani, M. Williams, R. Lewis, R. Moleron, N. Iqbal, N. Wadd, H. Lord, P. Bhat, G. Giamas, C. Lorimer, E. Chandy and G. Critchley (2024). "Glioblastoma in the UK post WHO CNS 5: initial findings from the Histo-Mol GBM collaborative." Neuro-Oncology 26(Supplement 7): vii2 EP - vii3.
B8. Sarcoma and Lymphoma
Articles
A. Santarsieri, E. Mitchell, M. H. Pham, R. Sanghvi, J. Jablonski, H. Lee-Six, K. Sturgess, P. Brice, T. F. Menne, W. Osborne, T. Creasey, K. M. Ardeshna, J. Baxter, S. Behan, K. Bhuller, S. Booth, N. D. Chavda, G. P. Collins, D. J. Culligan, K. Cwynarski, A. Davies, A. Downing, D. Dutton, M. Furtado, E. Gallop-Evans, A. Hodson, D. Hopkins, H. Hsu, S. Iyengar, S. G. Jones, M. Karanth, K. M. Linton, O. C. Lomas, N. Martinez-Calle, A. Mathur, P. McKay, S. K. Nagumantry, E. H. Phillips, N. Phillips, J. F. Rudge, N. K. Shah, G. Stafford, A. Sternberg, R. Trickey, B. J. Uttenthal, N. Wetherall, X. Y. Zhang, A. K. McMillan, N. Coleman, M. R. Stratton, E. Laurenti, P. Borchmann, S. Borchmann, P. J. Campbell, R. Rahbari and G. A. Follows (2024). "Procarbazine-induced Genomic Toxicity in Hodgkin Lymphoma Survivors." medRxiv. 05.
B. Vincenzi, A. Cortellini, A. Mazzocca, S. Orlando, D. Romandini, J. Aguilar-Company, I. Ruiz-Camps, C. Valverde Morales, S. Eremiev-Eremiev, C. Tondini, J. Brunet, R. Bertulli, S. Provenzano, M. Bower, D. Generali, R. Salazar, A. Sureda, A. Prat, M. Vasiliki, M. Van Hemelrijck, A. Sita-Lumsden, A. Bertuzzi, S. Rossi, A. Jackson, F. Grosso, A. J. X. Lee, C. Murphy, K. Belessiotis, U. Mukherjee, F. Pommeret, A. Loizidou, G. Gaidano, G. M. Dettorre, S. Grisanti, M. Tucci, C. A. M. Fulgenzi, A. Gennari, A. Napolitano and D. J. Pinato (2024). "Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry." Therapeutic advances in medical oncology 16: 17588359231225028.
B9. Upper Gastro-Intestinal
Articles
M. E. Booth, H. A. Clements, J. Helbrow, M. A. Baxter, C. W. Bleaney, M. A. Hawkins, S. R. Markar, C. J. Peters, E. C. Smyth and T. D. L. Crosby (2024). "United Kingdom and Ireland Oesophagogastric Cancer Group Cancer Update 2023." Clinical Oncology (Royal College of Radiologists) 36(9): e283-e291.
M. di Pietro, N. J. Trudgill, M. Vasileiou, G. Longcroft-Wheaton, A. W. Phillips, J. Gossage, P. V. Kaye, K. G. Foley, T. Crosby, S. Nelson, H. Griffiths, M. Rahman, G. Ritchie, A. Crisp, S. Deed and J. N. Primrose (2024). "National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett's oesophagus and stage I oesophageal adenocarcinoma." Gut 73(6): 897-909.
K. Foley, D. Shorthouse, E. Rahrmann, L. Zhuang, G. Devonshire, R. J. Gilbertson, R. C. Fitzgerald and B. A. Hall (2024). "SMAD4 and KCNQ3 alterations are associated with lymph node metastases in oesophageal adenocarcinoma." Biochimica et Biophysica Acta - Molecular Basis of Disease 1870(1): 166867.
C. Fong, B. Patel, C. Peckitt, E. Bourmpaki, L. Satchwell, S. Cromarty, S. Kidd, K. von Loga, M. Uhlik, R. Begum, T. Rana, T. Waddell, S. Darby, A. Bradshaw, T. Roques, C. Morgan, C. Rees, R. Herbertson, P. Das, C. Thompson, M. Hewish, R. Petty, F. Thistlethwaite, S. Rao, N. Starling, I. Chau and D. Cunningham (2024). "Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study." ESMO Open 9(7): 103622.
J. Helbrow, G. Lewis, C. Hurt, G. Radhakrishna, O. Nicholas, M. A. Hawkins, S. Mukherjee, J. Graby, T. Crosby and S. Gwynne (2024). "Radiotherapy Quality Assurance in the SCOPE2 Trial: What Lessons can be Learned for the Next UK Trial in Oesophageal Cancer?" Clinical Oncology (Royal College of Radiologists) 38: 103735.
D. Holland-Hart, M. Longo, S. Bridges, L. S. Nixon, M. Hawkins, T. Crosby and A. Nelson (2024). "The experiences of patients with oesophageal cancer receiving chemoradiotherapy treatment: a qualitative study embedded in the SCOPE2 trial." BMJ Open 14(9): e076394.
S. R. Javed, S. Lord, S. El Badri, R. Harman, J. Holmes, F. Kamzi, T. Maughan, D. McIntosh, S. Mukherjee, A. Ooms, G. Radhakrishna, P. Shaw and M. A. Hawkins (2024). "CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method." British Journal of Cancer 130(3): 467-475.
S. Mukherjee, C. Qi, R. Shaw, C. M. Jones, J. A. Bridgewater, G. Radhakrishna, N. Patel, J. Holmes, P. S. Virdee, B. Tranter, P. Parsons, S. Falk, H. S. Wasan, T. V. Ajithkumar, D. Holyoake, R. Roy, M. Scott-Brown, C. N. Hurt, E. O'Neill, D. Sebag-Montefiore, T. S. Maughan, M. A. Hawkins and P. Corrie (2024). "Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial." European Journal of Cancer 209: 114236.
D. H. Palmer, R. Jackson, C. Springfeld, P. Ghaneh, C. Rawcliffe, C. M. Halloran, O. Faluyi, D. Cunningham, J. Wadsley, S. Darby, T. Meyer, R. Gillmore, P. Lind, B. Glimelius, S. Falk, Y. T. Ma, G. W. Middleton, S. Cummins, P. J. Ross, H. Wasan, A. McDonald, T. Crosby, P. Hammel, D. Borg, S. Sothi, J. W. Valle, A. Mehrabi, P. Bailey, C. Tjaden, C. Michalski, T. Hackert, M. W. Buchler and J. P. Neoptolemos (2024). "Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 05.
C. J. Peters, Y. Ang, F. D. Ciccarelli, H. Coles, H. G. Coleman, G. Contino, T. Crosby, G. Devonshire, M. Eldridge, A. Freeman, N. Grehan, M. McCord, B. Nutzinger, S. Zamani, S. L. Parsons, R. Petty, A. D. Sharrocks, R. J. E. Skipworth, E. C. Smyth, I. Soomro, T. J. Underwood and R. C. Fitzgerald (2024). "A decade of the Oesophageal Cancer Clinical and Molecular Stratification Consortium." Nature Medicine 30(1): 14-16.
P. H. Pucher, S. A. Rahman, P. Bhandari, N. Blencowe, S. Chidambaram, T. Crosby, R. P. Evans, E. A. Griffiths, S. K. Kamarajah, S. R. Markar, N. Trudgill, T. J. Underwood and J. A. Gossage (2024). "Prevalence and Risk Factors for Malignant Nodal Involvement in Early esophago-gastric Adenocarcinoma: Results from the Multicenter Retrospective Congress Study (endosCopic resectiON, esophaGectomy or Gastrectomy For Early Esophagogastric Cancers)." Annals of Surgery 02: 02.
Conference Abstracts
A. Gordon, Z. Rajan, C. Y. K. Fong, C. Peckitt, L. Satchwell, S. Cromarty, S. Kidd, K. Piadel, B. Leamon, O. Zhitkov, M. Davidson, J. Thompson, N. R. Maisey, S. Darby, T. S. Waddell, C. Morgan, A. Bradshaw, N. Starling, I. Chau and D. Cunningham (2024). "1424P Maintenance capecitabine plus ramucirumab after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma (OGA): Final analysis from the PLATFORM trial." Annals of Oncology 35(Supplement 2): S888.
S. Markar, A. Guazzelli, A. Taylor, L. L. Jones, V. Jogarah, D. Cromwell, F. Landeiro, N. Maynard, J. Lagergren, F. Gleeson, T. Underwood, A. Moss and T. D. L. Crosby (2024). "Protocol for open-label, randomised, controlled trial of intensive surveillance vs. standard postoperative follow-up in patients undergoing surgical resection for oesophageal and gastric cancer (SARONG trial)." Journal of Clinical Oncology 42(3 Supplement).
M. Moehler, D. Y. Oh, K. Kato, J. Tabernero, M. Cruz-Correa, L. S. Wyrwicz, R. A. P. Cid, A. Cubillo, L. Evesque, L. Fornaro, E. Dotan, C. Morgan, L. Li, Y. Xu, T. Sheng, S. Yang, H. Hu and R. H. Xu (2024). "Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305." Annals of Oncology 35(Supplement 1): S160-S161.
D. J. Pinato, R. H. Jones, M. D. Forster, A. M. Joshua, J. Korolewicz, S. Benafif, K. Aboud, J. Liu, R. Cosman, J. Paull, J. Fairley, S. R. Edmondson and J. F. Spicer (2024). "Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in advanced esophagogastric cancers in a phase 1/2 trial." Journal of Clinical Oncology 42(3 Supplement).
E. Smyth, D. Griffiths, K. Cozens, C. Hurt, R. Waugh, R. Turkington, K. Foley, R. Roy, S. Sharma, A. Jurdi, M. C. Liu, S. Ngan, R. Owen, D. Chuter, C. Steel and G. Griffiths (2024). "A single arm phase II trial of trastuzumab deruxtecan in patients with gastro-oesophageal adenocarcinoma cancer who are ctDNA and HER2 positive: DECIPHER (TRIALS IN PROGRESS)." Annals of Oncology 35(Supplement 1): S199.
B10. Unknown Primary
Articles
S. Harvey, M. Stares, J.-A. Scott, T. J. V. Thottiyil, A.-M. Conway, R. Haigh, J. Brown, G. Knowles, S. Dasgupta, K.-K. Shiu, C. Mitchell, C. Barrie, N. Cook and S. Clive (2024). "Biomarkers of systemic inflammation provide additional prognostic stratification in cancers of unknown primary." Cancer Medicine 13(3): e6988.
Conference Abstracts
A. M. Conway, M. Robinson, M. Concannon, S. Clive, T. Tillett, K. K. Shiu, L. C. Medley, S. Dasgupta, E. Ahmed, K. Warrington, Z. Zair, T. Gillham, A. Davis, J. A. Scott, A. Taylor, M. Stares, C. Mitchell, P. Oliveria, G. Burghel and N. Cook (2024). "CUPCOMP: A multi-site UK trial in carcinoma of unknown primary: A comparison across tissue and liquid biomarkers." Journal of Clinical Oncology. Conference: Annual Meeting of the American Society of Clinical Oncology, ASCO 42(16 Supplement).
S. E. Walters, R. Webster, J. Randall, T. Rackley, E. S. Evans, M. Evans and N. Palaniappan (2024). "180 Long Term Outcomes following Unilateral Treatment for Squamous Cell Carcinoma of Unknown Primary." Radiotherapy and Oncology 192(Supplement 1): S211-S213.
B11. Urology
Articles
S. Berenato, M. Williams, O. Woodley, C. Mohler, E. Evans, A. E. Millin and P. A. Wheeler (2024). "Novel dosimetric validation of a commercial CT scanner based deep learning automated contour solution for prostate radiotherapy." Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) 122: 103339.
E. Day, J. Gavira, J. C. Tapia, G. Anguera and P. Maroto (2024). "What About Variant Histologies in Bladder Cancer?" European urology focus 10(2): 227-230.
K. Fizazi, A. Bernard-Tessier, G. Roubaud, T. Utriainen, P. Barthelemy, A. Flechon, J. van der Voet, G. Gravis, R. Ratta, R. Jones, O. Parikh, M. Tanner, E. S. Antonarakis, C. Baldini, N. Peters, C. Garratt, T. Ikonen, P. Pohjanjousi, H. Joensuu and N. Cook (2024). "Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer." NEJM evidence 3(1): EVIDoa2300171.
J. Gavira, J. C. Tapia, A. Romano, G. Anguera, M. Aguado, A. Piedra, F. Bosma, S. Sanchez, C. Martin, F. Algaba, Y. Arce, Y. C. T. Ramon and P. Maroto (2024). "Challenges of diagnosing homologous recombination deficiencies in metastatic prostate cancer: a six-year experience from a single institution." Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societes & of the National Cancer Institute of Mexico 26(10): 2749-2753.
S. Harding and A. Borley (2024). "Switching to a Fixed-dose Combined Pertuzumab and Trastuzumab With Recombinant Human Hyaluronidase Subcutaneous Injection to Treat Human Epidermal Growth Factor Receptor 2-positive Breast Cancer in Real-world UK Clinical Practice." Clinical Oncology (Royal College of Radiologists) 37: 103671.
R. H. Jones, K. Fizazi, N. D. James, T. L. Tammela, N. Matsubara, F. Priou, P. Beuzeboc, T. Lesimple, P. Bono, V. Kataja, J. A. Garcia, A. Protheroe, N. Shore, J. Aspegren, H. Joensuu, I. Kuss, S. Fiala-Buskies and E. Vjaters (2024). "Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer." Prostate Cancer & Prostatic Diseases 27(4): 786-789.
J. McGrane, R. Frazer, A. Challapalli, G. Ratnayake, Z. Boh, A. Clayton, C. Chau, A. Sharma, M. Elgendy, N. Charnley, W. Mohamed, S. Kingdon, A. Protheroe, A. Lydon, A. Halstead, V. Ford, I. Muazzam, D. Lee, G. J. Melendez-Torres and A. Bahl (2024). "Real world, multicentre patterns of treatment and survival in metastatic renal cell carcinoma with the UK Renal Oncology Collaborative (UK ROC): Is it time to look favourably on first-line immunotherapy containing combinations in all IMDC groups?" Cancer Medicine 13(12): e7327.
P. H. Patel, S. Dreibe, A. Reid, C. Parker, J. Murray, A. Pathmanathan, A. Tirona, J. Guevara, Y. E. Suh, J. Frew, N. Palaniappan, I. Syndikus, G. Attard, N. Tunariu and A. C. Tree (2024). "Stereotactic Body Radiotherapy for Oligoprogression in Castration-Resistant Prostate Cancer: Early Toxicity Analysis of the TRAP Trial." Clinical Oncology (Royal College of Radiologists) 36(9): 585-592.
A. Sharma, A. Bahl, R. Frazer, E. Godhania, N. Halfpenny, K. Hartl, D. Heldt, J. McGrane, S. Sahbaz Gulser, B. Venugopal, A. Ritchie and K. Crichton (2024). "Axitinib after Treatment Failure with Sunitinib or Cytokines in Advanced Renal Cell Carcinoma-Systematic Literature Review of Clinical and Real-World Evidence." Cancers 16(15): 30.
P. A. Wheeler, N. S. West, R. Powis, R. Maggs, M. Chu, R. A. Pearson, N. Willis, B. Kurec, K. L. Reed, D. G. Lewis, J. Staffurth, E. Spezi and A. E. Millin (2024). "Multi-institutional evaluation of a Pareto navigation guided automated radiotherapy planning solution for prostate cancer." Radiation oncology (London, England) 19(1): 45.
M. Young, J. C. Tapia, B. Szabados, A. Jovaisaite, F. Jackson-Spence, E. Nally and T. Powles (2024). "NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors." Clinical genitourinary cancer 22(3): 102072.
R. Frazer, J. A. Arranz, S. V. Estevez, O. Parikh, L. M. Krabbe, N. S. Vasudev, C. Doehn, N. Marschner, T. Waddell, W. Ince and P. J. Goebell (1639). "Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis." Current Oncology Reports 26(12): 1639-1650.
N. van As, C. Griffin, A. Tree, J. Patel, P. Ostler, H. van der Voet, A. Loblaw, W. Chu, D. Ford, S. Tolan, S. Jain, P. Camilleri, K. Kancherla, J. Frew, A. Chan, O. Naismith, J. Armstrong, J. Staffurth, A. Martin, I. Dayes, P. Wells, D. Price, E. Williamson, J. Pugh, G. Manning, S. Brown, S. Burnett and E. Hall (1413). "Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer." The New England journal of medicine 391(15): 1413-1425.
Conference Abstracts
A. Bahl, E. Foulstone, L. Ashurst, E. Renninson, P. White, A. Bravo, M. Afshar, C. Alifrangis, B. Venugopal, A. Thomson, A. Tran, J. Barber, H. C. Dearden, C. Kent, V. Kumar, M. Callaway and A. Challapalli (2024). "A phase II trial of cemiplimab alone or in combination with standard of care chemotherapy in locally advanced or metastatic penile carcinoma (EPIC trial)." Journal of Clinical Oncology 42(4 Supplement).
K. Fizazi, G. Roubaud, A. Bernard-Tessier, G. Gravis, A. Flechon, R. Ratta, P. Barthelemy, R. J. Jones, O. Parikh, A. Hussain, H. Van Der Voet, N. Cook, N. Peters, M. Tanner, R. H. Jones, C. Garratt, P. Pohjanjousi, T. Ikonen, C. H. Poehlein and E. S. Antonarakis (2024). "MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results." Journal of Clinical Oncology 42(4 Supplement).
K. Fizazi, G. Roubaud, A. Bernard-Tessier, G. Gravis, A. Flechon, R. Ratta, P. Barthelemy, R. J. Jones, O. A. Parikh, A. Hussain, J. C. M. van der Voet, N. Cook, M. M. E. Tanner, R. H. Jones, C. Garratt, T. Ikonen, P. Pohjanjousi, C. H. Poehlein and E. S. Antonarakis (2024). "1605P Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results." Annals of Oncology 35(Supplement 2): S968.
M. D. Linch, G. Leone, Y. N. S. Wong, R. J. Jones, P. Sankey, D. H. Josephs, S. J. Crabb, L. Harris, A. Tasnim, M. Rashid, S. A. Quezada, L. Ensell, A. Jayaram, M. Kayani, C. C. Pritchard, A. Freeman, A. Haider, G. Attard, C. Swanton and T. Marafioti (2024). "Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial." Journal of Clinical Oncology. Conference: Annual Meeting of the American Society of Clinical Oncology, ASCO 42(16 Supplement).
J. McGrane, R. Frazer, A. Bahl, A. Challapalli, P. Roy, M. Tuthill, C. Forde, J. M. Malik, X. Y. Jiang, S. M. Alam, E. C. E. Jones, N. Charnley, W. M. Mohamed, N. O. Moon, D. Parslow, T. R. Geldart, C. L. Dyke, J. C. Tapia, D. Lee and G. J. Melendez-Torres (2024). "1711P Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups?" Annals of Oncology 35(Supplement 2): S1026.
P. D. Nathan, N. Charnley, R. Frazer, J. McGrane, I. Muazzam, M. Pillai, S. Rudman, A. Sharma, R. Stevenson, B. Venugopal, J. D. Hickey, A. R. Ritchie and K. Liu (2024). "A UK real-world observational study of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Outcomes at 36 months post treatment initiation." Journal of Clinical Oncology 42(4 Supplement).
R. E. Seadon, J. C. Tapia, D. Matthews, J. Gavira-Diaz, M. Santoni, M. N. Young, L. Blondel, R. Flippot, G. Anguera, R. Frazer and J. P. M. Rey (2024). "Quality-of-Life (QoL) data published by clinical trials supporting drug approvals for renal cell carcinoma (RCC)." Annals of Oncology 35(Supplement 2): S1192.
J. C. Tapia, J. Gavira, D. Matthews, M. Santoni, M. N. Young, L. Blondel, R. Flippot, R. Frazer, G. Anguera and J. P. Maroto Rey (2024). "1556P Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe." Annals of Oncology 35(Supplement 2): S945-S946.
J. C. Tapia, J. Gavira, D. Matthews, M. Santoni, M. N. Young, L. Blondel, R. Flippot, R. Frazer, G. Anguera Palacios and J. P. Maroto Rey (2024). "2019P Disparities in urothelial carcinoma (UC) drug approval: Contrasting North America and Europe." Annals of Oncology 35(Supplement 2): S1163.
B12. Other
B12.1 Chemotherapy/Immunotherapy
Conference Abstracts
J. F. Spicer, D. J. Pinato, M. Forster, A. M. Joshua, J. Korolewicz, K. Aboud, C. Morton, J. Liu, R. Cosman, N. J. Main, J. Le Meur, J. Paull, S. R. Edmondson and R. H. Jones (2024). "Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (DEP CTX) in patients with advanced solid cancers in a phase 1/2 trial (P1/2)." Journal of Clinical Oncology. Conference: Annual Meeting of the American Society of Clinical Oncology, ASCO 42(16 Supplement).
B12.2 Palliative Care
Articles
K. Flanagan, V. Vickerstaff, P. Wheatstone, O. Minton, M. Taubert, B. Hudson and N. White (2024). "Virtual reality technology for pain management in advanced cancer." The Cochrane database of systematic reviews 11: CD016078.
E. Haire, C. Bralesford, J. Botting, E. Beasant and M. Taubert (2024). "Do not attempt cardiopulmonary resuscitation documentation: a quality improvement project." BMJ Supportive and Palliative Care 14(e1): E1453-E1457.
H. Lewis, M. Taubert and A. Nelson (2024). "Virtual consultations: the experience of oncology and palliative care healthcare professionals." BMC palliative care 23(1): 114.
M. Miller, R. Ford and B. Smithers (2024). "Fast track to cricket: occupational therapists in hospital palliative medicine." BMJ Supportive and Palliative Care 14(e1): E574-E576.
M. Taubert (2024). "Healthcare media interviews." BMJ supportive & palliative care 14(1): 87-89.
M. Taubert, J. I. Baker, A. Hudson and E. Harding (2024). "'Do Not Attempt CPR': how the pandemic changed perceptions and practice." Medicine (United Kingdom) 52(7): 426-428.
M. Taubert and T. Duffy (2024). "Change in definitions of advance and future care planning." BMJ (Clinical research ed.) 385: q827.
M. Taubert, R. Hackett and S. Tavabie (2024). "Artificial intelligence and large language models in palliative medicine clinical practice and education." BMJ supportive & palliative care.
S. Tavabie, Y. Ta, E. Stewart, O. Tavabie, S. Bowers, N. White, C. Seton-Jones, S. Bass, M. Taubert, A. Berglund, S. Ford-Dunn, S. Cox and O. Minton (2024). "Seeking Excellence in End of Life Care UK (SEECare UK): a UK multi-centred service evaluation." BMJ Supportive and Palliative Care 14(e1): E1395-E1401.
Conference Abstracts
M. Mann, T. Hamilton, A. Byrne, S. Sivell, E. Baddeley and A. Retzer (2024). "Are holistic needs assessments (HNA) being consistently implemented in adult cancer clinical practice?" BMJ Supportive and Palliative Care 14(Supplement 1): A26.
B12.3 Radiotherapy and Proton Therapy
Articles
T. J. Wood, A. T. Davis, J. Earley, S. Edyvean, U. Findlay, R. Lindsay, R. Plaistow and M. Williams (2024). "IPEM topical report: the first UK survey of cone beam CT dose indices in radiotherapy verification imaging for adult patients." Physics in medicine and biology 69(22).
B12.4 Miscellaneous
Articles
V. Coyle, C. Forde, D. F. McAuley, R. H. Wilson, M. Clarke, R. Plummer, M. Grayson, C. McDowell, A. Agus, A. Doran, A. L. Thomas, R. A. Barnes, R. Adams, I. Chau, D. Storey and R. McMullan (2024). "Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH): a randomized non-inferiority trial." Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 30(1): 92-99.
C. Eichhorn, D. Koeckerling, R. K. Reddy, M. Ardissino, M. Rogowski, B. Coles, L. Hunziker, S. Greulich, I. Shiri, N. Frey, J. Eckstein, S. Windecker, R. Y. Kwong, G. C. M. Siontis and C. Grani (2024). "Risk Stratification in Nonischemic Dilated Cardiomyopathy Using CMR Imaging: A Systematic Review and Meta-Analysis." JAMA 332(18): 1535-1550.
Z. Iyizoba-Ebozue, A. Fatimilehin, M. Kayani, A. Khan, M. McMahon, S. Stewart, C. Croney, K. Sritharan, M. Khan, M. Obeid, O. Igwebike, R. Batool, R. A-Hakim, T. Aghadiuno, V. Ruparel and K. O'Reilly (2024). "Unveiling Disparities: Exploring Differential Attainment in Postgraduate Training Within Clinical Oncology." Clinical Oncology (Royal College of Radiologists (Great Britain)) 36(6): e119-e127.
S. Keohane, J. Potts and M. Taubert (2024). "Sunglasses for painful red eye." BMJ Supportive & Palliative Care.
E. Mantzourani, H. Ahmed, J. Bethel, S. Turner, A. Akbari, A. Evans, M. Prettyjohns, G. John, R. Gunnarsson and R. Cannings-John (2024). "Clinical outcomes following acute sore throat assessment at community pharmacy versus general practice: a retrospective, longitudinal, data linkage study." The Journal of Antimicrobial Chemotherapy. 11.
G. C. M. Siontis, B. Coles, J. D. Haner, L. McGovern, J. Bartkowiak, J. J. Coughlan, A. Spirito, R. Galea, A. Haeberlin, F. Praz, D. Tomii, T. Melvin, A. Frenk, R. A. Byrne, A. G. Fraser and S. Windecker (2024). "Quality and transparency of evidence for implantable cardiovascular medical devices assessed by the CORE-MD consortium." European Heart Journal 45(3): 161-177.
M. Vasileva-Slaveva, D. Morales-Espinosa, A. Puccini, M. Meissner, M. Milic, G. Lamberti and R. Altena (2024). "Tackling hurdles in front of young clinical investigators in oncology - Results from an international survey." European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 50(6): 108031.
Conference Abstracts
P. Gallardo Melo, F. Bosma, A. Uruena, J. Garrillo Cepeda, J. Aguilar-Company, J. C. Tapia, J. Serna i Mont-Ros, L. Maciel Bravo, B. Martin Cullell, O. Mirallas, C. Gianella Blanco, C. Salva de Torres, S. Martinez Peralta, M. Aguado Sorolla, B. Alonso Martinez, S. Eremiev, M. Roca, S. Serradell, J. C. Galceran and P. Gomez Pardo (2024). "1479P Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study." Annals of Oncology 35(Supplement 2): S913-S914.
K. Williams, K. Baker and F. Rawlinson (2024). "Improving the documentation of mobility status for patients with Metastatic Spinal Cord Compression: a quality improvement project." Physiotherapy (United Kingdom) 123(Supplement 1): e85-e86.
K. Williams and J. Choi (2024). "Developing holistic management in Oncology Same Day Emergency Care (SDEC)." Physiotherapy (United Kingdom) 123(Supplement 1): e43.